Published in

American Diabetes Association, Diabetes Care, 7(32), p. 1269-1271, 2009

DOI: 10.2337/dc08-2271

Links

Tools

Export citation

Search in Google Scholar

Anti–Heat Shock Protein 27 Antibody Levels and Diabetes Complications in the EURODIAB Study

Journal article published in 2009 by Davina Burt, Graziella Bruno ORCID, Nish Chaturvedi, Stehouwer Cd, Casper Schalkwijk, Coen D. Stehouwer, Witte Dr, Daniel R. Witte ORCID, John H. Fuller, Fuller Jh, Silvia Pinach, Paolo Cavallo Perin, Paolo Cavallo Perin, Perin Pc, Gabriella Gruden
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

OBJECTIVE To assess whether serum anti–heat shock protein 27 (HSP27) antibody levels are associated with micro- and macrovascular complications of type 1 diabetes. RESEARCH DESIGN AND METHODS Anti-HSP27 IgG antibody levels were measured in 531 type 1 diabetic subjects recruited as part of the cross-sectional analysis of the EURODIAB Prospective Complications Study. Case subjects (n = 363) were defined as individuals with one or more diabetes complications and control subjects (n = 168) as individuals with no evidence of any diabetes complication. RESULTS Anti-HSP27 levels were comparable in case and control subjects (19.6 arbitrary units/ml [11.3–32.7] vs. 20.4 arbitrary units/ml [11.7–35.3], geometric mean [interquartile range]), and there was no correlation between HSP27 and anti-HSP27 levels (r = 0.01, P = 0.81). In logistic regression analysis, anti-HSP27 was not associated with the presence of complications, even after adjustment for main risk factors. CONCLUSIONS Anti-HSP27 antibody levels are not a marker of vascular complications in type 1 diabetes.